PETACH TIKVA, Israel, April 16, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today ...
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology. The agreement involves Daiichi Sankyo ...
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, today announced the ...
PETACH TIKVAH, Israel, March 23, 2026 /PRNewswire/ -- Interna Therapeutics, a clinical-stage biopharmaceutical company announced today that it has signed an agreement with the University of Oxford to ...
UTRECHT, The Netherlands--(BUSINESS WIRE)--InteRNA Technologies announced today that the first patient has been dosed in the first cohort of its first-in-human Phase I study with the Company’s lead ...
Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The ...
Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V. ("InteRNA"), a biopharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results